(Q63229172)
Statements
A Phase IIa, Open Label Pilot Study of Clemizole Hydrochloride Given Orally Thrice a Day, for Subjects With Hepatocellular Carcinoma That Are Either Awaiting Transplantation or Have an Unresectable Lesion (English)
0 references
13 February 2017
0 references
31 December 2017
0 references
12
0 references
18 year
0 references